Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria
The purpose of this research study is to see if a drug called ritlecitinib is safe and
effective for treating chronic spontaneous urticaria (CSU). CSU is hives and itching
lasting over six weeks. Ritlecitinib is approved by the Food and Drug Administration
(FDA) to t...
Age: 18 - 65 years
Gender: All
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
This study is open to adults who are at least 18 years old and have:
- a confirmed liver disease called non-alcoholic steatohepatitis
(NASH)/metabolic-associated steatohepatitis (MASH) and
- moderate or advanced liver fibrosis
People with a history of acute...
Age: 18 years - 66+
Gender: All
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
This study is open to adults who are at least 18 years old and have:
- A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or
- A confirmed liver disease called metabolic-associated steatohepatitis (MASH)
- BMI of 27 kg/m2 or more or
- ...
Age: 18 years - 66+
Gender: All
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
The purpose of this study is to find out whether a medicine called spesolimab helps
people with pyoderma gangrenosum (PG). The main aim is to see whether spesolimab leads to
closure of PG ulcers. This study is open to adults with ulcerative PG with at least 1
ulcer t...
Age: 18 years - 66+
Gender: All
Skin Pigment/Pulse Oximeter in Congenital Heart Disease (CHD)
Recent retrospective studies have demonstrated differences between pulse oximeter values (SpO2) and measured arterial oxygen saturation (SaO2) in patients identifying as Black or Hispanic. These retrospective studies have limitations because self-reported race is likely...
Age: Birth - 18 years
Gender: All
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness,
swelling), in the digestive tract, most frequently affecting the bowels. It can cause
many different symptoms including belly pain, diarrhea, tiredness, and weight loss.
Treatmen...
Age: 18 - 75 years
Gender: All
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease
which includes the forming of lumps, abscesses and scars in areas of the skin such as
under the breasts, under armpits, inner thighs, groin and buttocks. This study will
compare lu...
Age: 16 years - 66+
Gender: All
Spesolimab in Pyoderma Gangrenosum
The purpose of this research study is to assess the feasibility of using spesolimab in
participants with moderate to severe pyoderma gangrenosum. Pyoderma gangrenosum is a
rare, inflammatory, autoimmune condition which results in ulceration of skin. The study
will al...
Age: 18 years - 66+
Gender: All
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
The purpose of this study is to learn about the safety and effects of 2 study medicines
(PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long-
lasting itchy red rash, caused by a skin reaction.
This study is seeking participants wh...
Age: 18 years - 66+
Gender: All
Ritlecitinib in CTCL
The purpose of this research study is to evaluate the effectiveness and safety of
Ritlecitinib in skin and blood in persons with Cutaneous T-Cell Lymphoma (CTCL). CTCL is a
rare type of cancer that starts in the white blood cells and eventually can result in rashes
...
Age: 18 years - 66+
Gender: All
Study to Evaluate the Safety and Tolerability of Single-Dose Intravenous (IV) Oritavancin
This protocol describes a randomized, open-label study to evaluate the safety and
tolerability of single-dose intravenous (IV) oritavancin diphosphate (oritavancin) versus
standard of care (SoC) antibiotics for the treatment of pediatric subjects with acute
bacterial...
Age: 3 months - 17 years
Gender: All
Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases
This is a phase I, open label study employing diphencyprone (DPCP) to characterize gene
expression changes of various immune cell and tumor markers in cutaneous metastases
treated with topical DPCP twice weekly for 12 weeks in combination with PD-1 or PD-L1
immune ch...
Age: 18 years - 66+
Gender: All
Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis
This is a multi-center, longitudinal study which will characterize the gene expression
profiles and transcriptomic endotypes that underlie mild and moderate-severe Atopic
dermatitis (AD) and will determine changes in these expression patterns and endotypes in
respons...
Age: 6 years - 66+
Gender: All
Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
The purpose of this research study is to determine the safety and tolerability of two
dosing schedules of cemiplimab given in combination with cisplatin and docetaxel
induction chemotherapy (TPI) in patients with locally advanced squamous cell carcinoma of
the head a...
Age: 18 years - 66+
Gender: All
Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
The purpose of this research study is to determine the safety and tolerability of two
dosing schedules of cemiplimab given in combination with cisplatin and docetaxel
induction chemotherapy (TPI) in patients with locally advanced squamous cell carcinoma of
the head a...
Age: 18 years - 66+
Gender: All
Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Cancer
This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk
(Herceptin Hylecta [TM]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo [TM])
to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients
with HER...
Age: 18 years - 66+
Gender: Female
ERTU-SODIUM: Study on the Effects of Ertugliflozin on Sodium Storage, Interstitial Volume, and Plasma Volume in HFrEF
The overall hypothesis is that treatment with the SGLT2 inhibitor Ertugliflozin induces a differential regulation in interstitial fluid vs plasma volume, with more reduction of the volume from the interstitial fluid than from the circulating plasma volume, which results...
Age: 18 years - 66+
Gender: All
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
The purpose of this trial is to measure the safety and effectiveness of epcoritamab
(EPKINLY™), either by itself or together with other therapies, when treating subjects
with B-cell non-Hodgkin Lymphoma (B-NHL). The aim of the first part of the trial is to
identify t...
Age: 18 years - 66+
Gender: All
A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis
This will be a single-center, open-label clinical study to determine the efficacy and safety of secukinumab in the treatment of moderate to severe psoriasis vulgaris in skin of color (SOC) (FST IV-VI). This study will also evaluate the degree of erythema versus hyperpig...
Age: 18 years - 66+
Gender: All
Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS
ZYN002 is a pharmaceutically manufactured Cannabidiol that is developed as a clear gel
that can be applied to the skin (called transdermal delivery).
The gel will be applied to clean, dry, intact skin of the shoulders and/or upper arms.
Participants from the ZYN2...
Age: 3 - 24 years
Gender: All